Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FMS 
Fresenius Medical Care Corporation (FMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/20/2025: FMS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $28.94
1 Year Target Price $28.94
| 1 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.93% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/20/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.94B USD | Price to earnings Ratio 20.89 | 1Y Target Price 28.94 |
Price to earnings Ratio 20.89 | 1Y Target Price 28.94 | ||
Volume (30-day avg) 6 | Beta 0.89 | 52 Weeks Range 18.43 - 29.71 | Updated Date 10/20/2025 |
52 Weeks Range 18.43 - 29.71 | Updated Date 10/20/2025 | ||
Dividends yield (FY) 2.90% | Basic EPS (TTM) 1.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.36% | Operating Margin (TTM) 8.23% |
Management Effectiveness
Return on Assets (TTM) 3.03% | Return on Equity (TTM) 5.72% |
Valuation
Trailing PE 20.89 | Forward PE 10.55 | Enterprise Value 26538885989 | Price to Sales(TTM) 0.82 |
Enterprise Value 26538885989 | Price to Sales(TTM) 0.82 | ||
Enterprise Value to Revenue 1.16 | Enterprise Value to EBITDA 7.14 | Shares Outstanding 586826898 | Shares Floating 208473190 |
Shares Outstanding 586826898 | Shares Floating 208473190 | ||
Percent Insiders - | Percent Institutions 8.02 |
Upturn AI SWOT
Fresenius Medical Care Corporation
Company Overview
History and Background
Fresenius Medical Care was founded in 1996 through the merger of Fresenius AG's dialysis division and National Medical Care. It has grown to become a leading provider of dialysis products and services worldwide.
Core Business Areas
- Dialysis Services: Provides dialysis care to patients with chronic kidney failure through a network of dialysis centers.
- Dialysis Products: Manufactures and distributes a wide range of dialysis machines, dialyzers, and other related products.
- Renal Pharmaceuticals: Develops and markets pharmaceuticals used in the treatment of kidney disease.
Leadership and Structure
The company is led by a Management Board. The organizational structure includes regional segments and global functions.
Top Products and Market Share
Key Offerings
- Dialysis Machines (4008S, 5008S): These machines perform hemodialysis. Fresenius is a leader in this market, competing with Baxter and Nikkiso. Market share for specific machine models is proprietary, but the company holds a significant portion of the overall dialysis machine market. Revenue from this product is substantial but not publicly broken down. Competitors include Baxter, B. Braun, and Nikkiso.
- Dialyzers (FX CorDiax, Optiflux): These filters remove waste and excess fluid from the blood. Fresenius is a leading supplier of dialyzers. Competitors include Asahi Kasei Medical, Nipro, and Baxter. Market share is significant.
- Renal Pharmaceuticals (Calcijex, Velphoro): These medications manage complications of kidney disease. Competitors include Sanofi, Amgen, and various generic manufacturers. Fresenius aims to enhance its presence in the pharmaceutical market.
Market Dynamics
Industry Overview
The dialysis services and products industry is characterized by increasing prevalence of chronic kidney disease (CKD), an aging population, and technological advancements in dialysis therapies. It's highly regulated and consolidated.
Positioning
Fresenius Medical Care is one of the largest providers of dialysis services and products globally. Its competitive advantages include a large global network of dialysis clinics, a comprehensive product portfolio, and a strong brand reputation.
Total Addressable Market (TAM)
The global dialysis market is projected to reach several billion dollars annually. Fresenius, as a market leader, is well-positioned to capture a significant share of this market. Expected TAM is > $90B by 2030.
Upturn SWOT Analysis
Strengths
- Global network of dialysis clinics
- Comprehensive product portfolio
- Strong brand reputation
- Established relationships with healthcare providers
Weaknesses
- High debt levels
- Exposure to reimbursement pressures
- Operational challenges in certain markets
- Litigation risks
Opportunities
- Expanding dialysis services in emerging markets
- Developing innovative dialysis technologies
- Acquiring smaller dialysis providers
- Growing the renal pharmaceuticals business
Threats
- Increasing competition from other dialysis providers
- Changes in government regulations and reimbursement policies
- Technological disruptions
- Economic downturns
Competitors and Market Share
Key Competitors
- BAX
- DVA
- BIO
Competitive Landscape
Fresenius Medical Care benefits from its scale and global presence, but faces intense competition from other large dialysis providers and product manufacturers.
Major Acquisitions
NxStage Medical
- Year: 2019
- Acquisition Price (USD millions): 2000
- Strategic Rationale: Expanded Fresenius' portfolio in home dialysis and critical care products.
Growth Trajectory and Initiatives
Historical Growth: Fresenius Medical Care's historical growth has been driven by organic expansion of its dialysis services and products business, as well as acquisitions.
Future Projections: Analyst estimates depend on many factors.
Recent Initiatives: Recent strategic initiatives may include expanding into new markets, developing new dialysis technologies, and acquiring smaller dialysis providers.
Summary
Fresenius Medical Care is a leading provider of dialysis services and products with a strong global presence. While benefiting from its scale and comprehensive portfolio, the company faces challenges related to debt, reimbursement pressures, and competition. Opportunities exist in emerging markets and technological innovations, but regulatory changes and economic conditions pose threats. Overall, Fresenius' stability depends on managing its debts and navigating the competitive environment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, analyst estimates, news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fresenius Medical Care Corporation
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-09-19 | Chair of Management Board & CEO Ms. Helen Giza | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 112445 | |
Full time employees 112445 | |||
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, ambulant treatment, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.